Presymptomatic Diabetes Type 1 (Stage 1)

Metabolic Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

PolTREG
PolTREGPoland - Gdańsk
1 program
1
ex vivo expanded CD4+CD25+CD127- regulatory T cellsPhase 21 trial
Active Trials
NCT06688331RecruitingEst. Dec 2032

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
2031
PolTREGex vivo expanded CD4+CD25+CD127- regulatory T cells

Clinical Trials (1)

NCT06688331PolTREGex vivo expanded CD4+CD25+CD127- regulatory T cells

Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody

Start: Mar 2025Est. completion: Dec 2032
Phase 2Recruiting

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space